Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: FK reports no potential competing interests. MCD has received consultancy fees from Baxter (data and safety monitoring board and lecture fees); Grifols/Talecris, Novartis, Octapharma (lecture fees and serving on DSMB); Alexion, Argenx and Dysimmune Diseases Foundation (consulting fees). He serves as an Associate Editor for Neurology (N2) and TAND. HCL received honoraria for speaking and advisory board engagement or academic research support by Akcea, Alnylam, Biogen, Celgene, CSL Behring, Grifols, Gruenenthal, LFB Pharma, Takeda and UCB."

"Funding: The authors received no financial support for the research, authorship and/or publication of this article."